Vertex Diabetes Cell Therapy Back On Track After FDA ‘Hiccup’
Regulator Lifts Clinical Hold
The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.
